Journal for ImmunoTherapy of Cancer

Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis

Celine Man Ying Li,[1,2] Yoko Tomita,[2,3] Bimala Dhakal,[1,2] Runhao Li [ID] ,[2,3] Jun Li,[4] Paul Drew,[1,2] Timothy Price,[2,3] Eric Smith,[2,3] Guy J Maddern,[1,2] Kevin Aaron Fenix [ID] [1,2]

[1]Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
[2]Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
[3]Medical Oncology, The Queen Elizabeth Hospital and The University of Adelaide, Adelaide, South Australia, Australia
[4]Urinary Surgery of Zhumadian Central Hospital, Zhumadian, Henan, China

Correspondence to
Dr Kevin Aaron Fenix;
kevin.fenix@adelaide.edu.au

ABSTRACT

Background The number of clinical studies evaluating the benefit of cytokine-induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer (CRC) is increasing. In many of these trials, CIK therapy was coadministered with conventional cancer therapy. The aim of this review is to systematically assess the available literature, in which the majority were only in Chinese, on CIK therapy for the management of CRC using meta-analysis and to identify parameters associated with successful CIK therapy implementation.

Methods Prospective and retrospective clinical studies which compared CIK therapy to non-CIK therapy in patients with CRC were searched for electronically on MEDLINE, Embase, China National Knowledge Infrastructure, and Wanfang Data databases. The clinical endpoints of overall survival (OS), progression-free survival (PFS), OS and PFS rates, overall response rate (ORR), and toxicity were meta-analyzed using HR and relative ratio (RR), and subgroup analyses were performed using chi-square (χ^2) test and I-squared (I^2) statistics for study design, disease stage, cotherapy type, and timing of administration.

Results In total, 70 studies involving 6743 patients were analyzed. CIK therapy was favored over non-CIK therapy for OS (HR=0.59, 95% CI: 0.53 to 0.65), PFS (HR=0.55, 95% CI: 0.47 to 0.63), and ORR (RR=0.65, 95% CI: 0.57 to 0.74) without increasing toxicity (HR=0.59, 95% CI: 0.16 to 2.25). Subgroup analyses on OS and PFS by study design (randomized vs non-randomized study design), disease stage (Stage I–III vs Stage IV), cotreatment with dendritic cells (DCs) (CIK vs DC-CIK therapy), or timing of therapy administration (concurrent vs sequential with coadministered anticancer therapy) also showed that the clinical benefit of CIK therapy was robust in any subgroup analysis. Furthermore, cotreatment with DCs did not improve clinical outcomes over CIK therapy alone.

Conclusion Compared with standard therapy, patients who received additional CIK cell therapy had favorable outcomes without increased toxicity, warranting further investigation into CIK therapy for the treatment of CRC.

INTRODUCTION

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide.[1]

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Cytokine-induced killer cell (CIK) therapy is an adoptive immunotherapy used to treat both solid and hematological cancers for over 20 years. It is predominantly used in China, with multiple studies reporting benefits in patients with colorectal cancer (CRC). Despite this, CIK therapy treatment regimens are not widely used, possibly due in part to the majority of the literature about CIK therapy in CRC being reported in Chinese. Further, CIK therapy is commonly combined with other therapies but it is currently not known if there is a specific combination or treatment regimen that is optimal for CRC.

WHAT THIS STUDY ADDS

⇒ We report the most comprehensive systematic review to date of CIK therapy for patients with CRC, combining both Chinese and English language reports. Patients with CRC who received additional CIK therapy had better survival outcomes than with standard therapy alone. We also showed that the addition of dendritic cells to CIK therapy, common for CRC treatment, did not provide any clinical benefit over CIK therapy alone and that CIK therapy is effective whether given concurrently or sequentially to standard treatment regimens.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Our systematic review of Chinese and English publications shows that patients with CRC benefit from the addition of CIK therapy to standard treatment protocols and warrants further international studies.

Patients with locally advanced CRC, including regional lymph node metastases, have a 5-year survival of 75%, which reduces to 15% if there are distant metastases.[2] Survival outcomes for locally advanced and metastatic CRC have steadily improved due to advancements in surgical techniques, perioperative care, and

therapeutic options. However, tumor recurrence and therapy resistance remain a challenge, creating the need for new treatment options.[3]

During the last decade, immunotherapy has revolutionized cancer treatment, with clinical efficacy established for multiple solid and hematological cancers.[4] Immune checkpoint inhibitors have provided significant clinical benefit, particularly in solid cancers with a high tumor mutation burden.[5] In advanced CRC cases, they have become the standard of care for high microsatellite instability/deficient mismatch repair tumors.[6 7] Adoptive immunotherapy involves the administration of immune cells expanded and modified in ex vivo culture. Most treatments have focused on chimeric antigen receptor T (CAR-T) cell therapy. However, other technologies including dendritic cell (DC) therapy, natural killer (NK) cell therapy, and cytokine-induced killer cell (CIK) therapy are being studied. Unlike immune checkpoint inhibitors, none of the adaptive immunotherapy products are Food and Drug Administration approved for CRC treatment.[8]

CIK therapy is an autologous, adoptive immunotherapy generated by expanding a heterogeneous population of immune effector cells from peripheral blood mononuclear cells (PBMCs).[9] The cell therapy product contains conventional T cells (CD3+CD56−), natural killer (NK)-like T cells (CD3+CD56+), and NK cells (CD3−CD56+).[10] NK-like T cells are considered the main effector cells in CIK therapy, being able to recognize tumor cells in a major histocompatibility complex class I unrestricted manner.[11 12] Hence, guidelines for CIK therapy patient transfusion require that the cell therapy product contain at least 40% of NK-like T cells.[13] While CIK therapy is normally combined with conventional chemotherapy, multiple trials which combine CIK therapy with other immunotherapies are being investigated. One of the more popular combinations is combining CIK therapy with autologous DC therapy (DC-CIK therapy) with reports suggesting an improvement in antitumor activity.[14] China has been a leader in CIK therapy trials for multiple solid tumors, and CIK therapy is commonly provided for CRC treatment in some Chinese hospitals.[15 16]

To date, there is a plethora of publications of varying study quality examining the clinical benefit of CIK therapy for CRC. The latest systematic review investigating the clinical efficacy of CIK therapy with chemotherapy in patients with CRC was published in 2017.[16] Since then more studies have been published that support its clinical benefit,[17–20] warranting an updated systematic review to consolidate the evidence for CIK therapy in CRC management. Many of the reports originate in China and are written in Chinese. The objective of this work, therefore, is to systematically assess by meta-analysis the available literature on CIK therapy for the management of CRC, written in either English or Chinese. It includes both prospective and retrospective studies and also analyzed the benefit of parameters commonly modified in trials,

such as the addition of DCs (DC-CIK therapy) or chemotherapy regimens.

METHODS

This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement.[21]

Study selection and search

Studies which compared efficacy of CIK therapy, with or without another anticancer treatment, with no treatment or non-CIK anticancer treatment in adult patients with CRC diagnosis were identified on MEDLINE, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang Data databases. CNKI and Wanfang Data were included as there were multiple studies published in Chinese alone, which were not registered with Embase or MEDLINE. The search strategy for Embase and MEDLINE is described in online supplemental tables S1 and S2, respectively. For CNKI and Wanfang Data, the following search keywords were used: "cytokine-induced killer cells," "CIK," "rectal cancer," "colorectal cancer," "colon cancer," and "clinical trials." No limits were placed on the language in which studies were published and the final search was performed in July 2022. Both prospective and retrospective studies with a parallel-arm design were considered, and the CIK therapy arm included patients who received CIK or DC-CIK (CIK/DC-CIK) therapy. Studies that did not report efficacy endpoints were excluded from this systematic review.

Data extraction and quality assessment

Data collection was performed independently by two authors, and discrepancies were resolved by discussion. For studies reported in Chinese, authors who are native to the Chinese language performed the data extraction and translated them into English for collation. The following information was extracted: (1) study characteristics: study design, study site, and recruitment period; (2) patient and disease characteristics: number of patients, age, gender, primary tumor location, and tumor stage; (3) study intervention: type of CIK therapy and non-CIK anticancer therapy received; (4) clinical efficacy endpoints: overall survival (OS); progression-free survival (PFS); 1-year, 3-year, and 5-year OS rates; 1-year, 3-year, and 5-year PFS rates; and overall response rate (ORR); and (5) toxicity.

For studies where patients received curative-intent treatment, disease-free survival (DFS) and DFS rates were extracted as PFS and PFS rates. Risk of bias was assessed for the following domains and graded as high, low, or unclear: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) imbalance in baseline characteristics, (6) incomplete outcome data, and (7) uniformity of non-CIK/DC-CIK

anticancer treatment administered between intervention and control arms.

Data synthesis and analysis

Review Manager 5.4.1[22] was used for pooling data at the study level and statistical analysis. For the multi-intervention-arm study, the control arm was split equally into each intervention arm, so that each pairwise comparison can be entered separately. Pooled estimates of effect were expressed as a HR calculated using an inverse variance model for OS and PFS, and risk ratios (RRs) were calculated using the Mantel-Haenszel model for survival rates and ORRs. When individual studies did not describe OS and/or PFS HRs and associated 95% CIs, they were estimated from the published Kaplan-Meier curves using a previously described method.[23 24] The HR and 95% CI were estimated under the assumption of Gaussian distribution for the study that reported median PFS with a p-value.[25]

As heterogeneity due to clinical diversity was expected to be high, a random-effects model was used for all the quantitative analyses performed in this review. Heterogeneity across studies was further assessed by visual inspection and statistical using chi-square (χ^2) test and I-squared (I^2) statistics for each analysis. A p-value threshold of 0.10 was employed to determine statistical significance for χ^2 test, and I^2 of 30% or less was considered to be a low degree of heterogeneity, 30% to 60% to be a moderate degree, and 60% or more to be a high degree.

Subgroup analyses were carried out on OS and PFS endpoints to investigate possible sources of heterogeneity. The following subgroup analyses were performed in this review: (1) quality of study design: randomized studies versus non-randomized studies, (2) cancer staging: Stage I–III after resection of primary versus Stage IV (unresectable, metastatic, or recurrent) CRC, (3) CIK therapy type: CIK therapy versus DC-CIK therapy, and (4) CIK therapy administration timing in relation to other anticancer therapy: concurrent versus sequential. The subgroup interactions were tested by using the formal statistical test, χ^2 test, with significance set at 10%.

RESULTS
Search results

Through our electronic search, 333 records were identified: 129 from Embase, 38 from MEDLINE, 60 from CNKI, and 106 from Wanfang Data. After removing duplicate publications and studies in which titles and/or abstracts indicated were ineligible, 106 records were assessed in detail. An additional 36 records were excluded for only a single study arm, lack of information on clinical efficacy endpoints of interest, overlapping patient cohorts with another publication, being unable to extract data specific to patients with CRC, inability to locate original abstracts or full-text articles, patients in all study arms receiving CIK therapy, and patients in the control arm being healthy subjects. Thus, 70 studies containing 16 English[17–20 26–37] and 44 Chinese[26 38–90] language articles were selected for study synthesis (figure 1).

Study and patient characteristics

Standardized study cohorts are summarized in table 1. Two studies[18 90] were abstracts with the rest being full-text articles. All studies were single-center studies performed in mainland China. Fifty-four studies[25–27 30 32 34 35 38–40 42–51 53 55–61 63–73 75 76 78–81 83–89 91] were prospective and 15 studies[17–20 29 33 36 37 41 52 54 62 74 77 82] were retrospective in nature. Of the prospective studies, 38[18 19 27 28 31 35 36 38 39 43–46 48 49 51 52 56 58 60–62 64–68 71–74 79–82 84 86 88 90] were randomized controlled studies.

Overall, 6743 patients with CRC, 3203 in CIK therapy (intervention) arm, and 3540 in non-CIK therapy (control) arm were available for analysis. The median age ranged from 43.2 to 80.0 years old with the youngest being 18 and the oldest being 92 years old. For studies which provided the patient's gender, 3592 out of 6017 patients (59.7%) were males. Primary tumor location was reported in 30 studies, with 1657 colon and 1744 rectum cancer patients. Patients with CRC diagnosed with all cancer stages were considered for analysis. Three studies evaluated purely patients with Stage III CRC,[50 52 63] while 29 studies evaluated patients with Stage IV CRC.[20 26 28 30 35 37 40 44 46 48 51 57 58 60 66–68 73–76 78 82 83 85 87–89] The remaining studies considered patients with multiple stages. Among patients with known cancer stages, 3109 (66.6%) of them had Stage IV disease, comprising the largest group followed by 1148 patients (24.5%) with Stage III disease, 375 patients with Stage II disease, and 46 patients with Stage I disease. Cancer staging for the remaining 1672 patients was either unknown or reported in ranges.

Interventions

In 25 studies,[17 18 20 26 28 29 32–36 38 39 44 45 47–49 54 56 63 69 73 75 85] patients in the intervention arm received CIK therapy, while in 45 studies[19 25 27 30 31 37 40–43 46 50–53 55 57–62 64–68 70–72 74 76–84 86–89 91] DC-CIK therapy was administered. Chemotherapy was the most common cotreatment with CIK or DC-CIK therapy, being used in 66 studies.[17–20 25–27 29–53 55–78 80–88 91] The most commonly used chemotherapy regimens were FOLFOX and XELOX, being administered in 43[17 18 26 30–32 34–38 40 42 44 47 49 50 54 56–65 68–70 72–75 77 78 81–84 87 90] and 24[17 27 28 31 32 34 35 37 39–41 46 57 66 69 71 85 86 88] studies, respectively. Other less commonly used regimens included 5-fluorouracil monotherapy in six studies,[30 33 36 39 53 77] capecitabine monotherapy in seven studies,[17 33 36 53 56 75 82] FOLFIRI in eight studies,[19 20 41 46 74 76 81 86] and FOLFOXIRI in two studies.[74 86] In total, 2847 patients in the intervention arm and 3033 patients in the control arm were confirmed to have received chemotherapy as a part of the study intervention. In 10 studies, local therapy was administered together with CIK/DC-CIK therapy: radiofrequency ablation in three studies,[28 74 86] radiotherapy in six studies,[19 47 50 54 56 77] transarterial chemoembolization in

Figure 1 Flow chart of study selection.

one study,[88] and microwave hyperthermia in one study.[54] In two studies, some or all patients in the intervention arm received CIK/DC-CIK therapy alone.[41 79]

Risk of bias assessment

Risk of bias assessment is shown in online supplemental figure 1. Among the 38 studies reported to be prospective randomized controlled studies, only nine studies[27 32 35 43 59 66 70 78 89] described the method of randomization and no study discussed allocation concealment. None of the included studies provided clarity on the blinding of patients, study personnel, or investigators. However, it was considered unlikely that a lack of blinding would affect the clinical efficacy endpoints evaluated in the review, namely OS, PFS, OS rate and PFS rate, and ORR. All the studies were thus assessed to be at low risk of performance and detection bias secondary to insufficient blinding. Demographic and clinical characteristics of patients were generally well-balanced across the studies. Four studies[18 27 49 58] were at unclear

risk of selection bias due to a lack of patient characteristics information across treatment arms. Imbalance in age, cancer stage, and history of primary cancer resection were noted for three studies,[17 36 37] and they were similarly assessed to be at unclear risk of selection bias. An unclear risk of performance bias due to uncertainty around uniformity of non-CIK/DC-CIK treatment across the intervention and control arms was identified in 21 studies[18 20 27 30 33 37 41 42 46 50 51 53 56 60 74 77–79 81 82 86] with all the studies except one failing to adequately describe study interventions or the proportion of patients receiving various interventions. In the remaining one study,[79] patients in the intervention arm received DC-CIK therapy alone, while those in the control arm received the best supportive care. The risk of attrition bias was rated unclear for 18 studies[17–20 26 28 30 32 34–38 40 66 77 81 83 88] which did not reveal the number of patients lost in follow-up and for one study[36] in which 18.8% of patients withdrew from the study prematurely.

Table 1 Summary of included studies

Study ID	Study type	RCT	Patient (n)	Age, years (range)	Male (%)	Colon primary (%)	Stage	Intervention arm(s) (n)	Control arm (n)	Outcomes
Bian et al[91]	P	Yes	84	39–78	54.8	73.8	I–III	DC-CIK+ChT (42)	ChT (42)	OS, PFS, ORR, SE
Cai et al[38]	P	Yes	80	–	62.5	–	II–III	CIK+ChT (40)	ChT (40)	OS, PFS, SE
Cai and Li[39]	P	No	72	–	69.4	0.0	I–III	CIK+ChT (40)	ChT (32)	OS, SE
Cai[40]	P	No	90	30–70	70.0	–	IV	DC-CIK+ChT (45)	ChT (45)	OS, PFS, SE
Chao et al[41]	R	No	66	–	68.2	–	III–IV	DC-CIK±ChT (33)	No treatment or ChT (33)	OS, SE
Chen et al[42]	P	Yes	60	30–65		100.0	III–IV	DC-CIK+ChT (30)	ChT (30)	OS, PFS, SE
Chen[43]	P	Yes	90	32–76	65.0	–	I–III	DC-CIK+ChT (45)	ChT (45)	OS, PFS
Chu et al[44]	P	Yes	89	–	51.7	–	IV	CIK (30) and CIK+ChT (29)	ChT (30)	OS, PFS, SE
Deng et al[45]	P	Yes	60	–		–	III–IV	CIK+ChT (30)	ChT (30)	OS, PFS, SE
Dong[46]	P	No	40	18–75	52.5	37.5	IV	DC-CIK+ChT (20)	ChT (20)	OS, PFS, SE
Du et al[26]	P	Yes	60	–	53.3	68.3	IV	CIK+ChT (30)	ChT (30)	OS, PFS, SE
Fan et al[47]	P	Yes	81	32–83		0.0	I–III	CIK+ChT+RT (41)	ChT+RT (40)	OS, PFS, ORR, SE
Fang[48]	P	Yes	52	–	59.6	–	IV	CIK+ChT (26)	ChT (26)	ORR, SE
Feng et al[49]	P	No	40	51–55	70.0	–	I–III	CIK+ChT (20)	ChT (20)	OS, PFS
Feng and Wang[50]	P	Yes	50	41–79	66.0	–	III	DC-CIK+ChRT (25)	ChRT (25)	PFS, ORR, SE
Gao et al[27]	P	No	26	–		–	<IV	DC-CIK+ChT (13)	No treatment (13)	OS, PFS, SE
Guo and Ma[51]	P	Yes	68	41–83	57.4	27.9	IV	DC-CIK+ChT (34)	ChT (34)	ORR
He and Zhang[52]	R	–	100	40–80	60.0	–	III	DC-CIK+ChT (50)	ChT (50)	OS, ORR
Jiang[53]	P	No	98	22–78	64.3	–	III–IV	DC-CIK+ChT (50)	ChT (48)	ORR
Leng et al[54]	R	–	90	29–66	57.8	0.0	III–IV	CIK+IMRT+microwave hyperthermia (45)	IMRT+microwave hyperthermia (45)	ORR, SE
Li et al[55]	P	Yes	40	–	70.0	–	II–III	DC-CIK+ChT (20)	ChT (20)	OS, ORR
Li et al[56]	P	No	130	–	56.2	43.0	II–III	CIK+ChT+RT (65)	ChT+RT (65)	ORR, SE
Li et al[28]	U	–	60	–	63.3	63.3	IV	CIK+RFA (30)	RFA (30)	ORR, SE
Li et al[29]	R	–	137	–	60.6	–	II–IV	CIK+ChT (66)	ChT (71)	ORR, SE
Lin et al[30]	P	Yes	255	–	54.9	56.1	IV	DC-CIK+ChT (134)	ChT (121)	OS
Liu[57]	P	Yes	56	32–72	55.4	–	IV	DC-CIK+ChT (28)	ChT (28)	ORR, SE
Liu et al[58]	P	No	18	28–73	55.6	–	IV	DC-CIK+ChT (9)	ChT (9)	ORR, SE

Continued

Table 1 Continued

Study ID	Study type	RCT	Patient (n)	Age, years (range)	Male (%)	Colon primary (%)	Stage	Intervention arm(s) (n)	Control arm (n)	Outcomes
Liu et al[60]	P	Yes	58	35–80	63.8	–	IV	DC-CIK+ChT (29)	ChT (29)	ORR
Liu et al[61]	P	Yes	80	22–82	61.3	–	I-IV	DC-CIK+ChT (40)	ChT (40)	ORR
Liu et al[62]	R	–	90	–	64.4	0.0	I-IV	DC-CIK+ChT (45)	ChT (45)	ORR
Lin et al[31]	P	Yes	70	–	68.6	40.0	II-IV	DC-CIK+ChT (35)	ChT (35)	OS, ORR, SE
Liu[59]	P	Yes	68	30–79	59.7	69.1	III-IV	DC-CIK+ChT (34)	ChT (34)	OS
Lv et al[63]	P	Yes	85	–	51.8	–	III	CIK+ChT (43)	ChT (42)	ORR, SE
Ma[64]	P	Yes	50	49–77	60.0	–	II-III	DC-CIK+ChT (25)	ChT (25)	ORR, SE
Niu[65]	P	Yes	50	34–62	64.0	–	III-IV	DC-CIK+ChT (25)	ChT (25)	ORR
Pan et al[20]	R	–	252	–	61.5	63.5	IV	CIK+ChT (126)	ChT (126)	OS, PFS
Pan et al[17]	R	–	122	–	63.9	64.8	II-IV	CIK+ChT (60)	ChT (62)	ORR
Peng et al[32]	P	Yes	46	–	63.0	–	II-III	CIK+ChT (23)	ChT (23)	ORR
Pu et al[66]	P	Yes	98	–	38.8	–	IV	DC-CIK+ChT (49)	ChT (49)	SE
Rui et al[67]	P	Yes	90	18–60	57.8	53.3	IV	DC-CIK+ChT (45)	ChT (45)	OS, ORR
Sun[68]	P	No	60	41–68	51.7	–	IV	DC-CIK+ChT (30)	ChT (30)	OS, ORR, SE
Wang et al[69]	P	No	110	–	60.0	63.6	I-III	CIK+ChT (55)	ChT (55)	OS, ORR
Wang et al[70]	P	Yes	104	32–69	58.7	–	III-IV	DC-CIK+ChT (52)	ChT (52)	ORR
Wang et al[71]	P	Yes	68	–	64.1	–	III-IV	DC-CIK+ChT (34)	ChT (34)	OS, ORR, SE
Wang et al[18]	R	–	377	–		–	–	CIK+ChT (97)	ChT (280)	ORR
Weng et al[72]	P	Yes	235	–	55.3	56.6	III-IV	DC-CIK+ChT (124)	ChT (111)	ORR
Weng et al[73]	P	Yes	96	25–76	59.6	–	IV	CIK+ChT (48)	ChT (48)	ORR
Wu[74]	R	–	132	–	66.7	51.5	IV	DC-CIK+ChT+RFA (62)	ChT+RFA (70)	OS
Xie et al[19]	R	–	142	–	55.6	–	III-IV	DC-CIK+ChT±RT (71)	ChT±RT (71)	OS, ORR
Xu et al[33]	R	–	116	–	46.6	54.3	II-IV	CIK+ChT (32)*	ChT (82)*	OS, ORR
Yan et al[75]	P	No	114	–	56.1	–	IV	CIK+ChT (72)	ChT (42)	OS, PFS, ORR
Yin[76]	P	No	80	–	61.3	60.0	IV	DC-CIK+ChT (40)	ChT (40)	OS, PFS, ORR
Ying et al[77]	R	–	102	20–86	54.9	–	I-III	DC-CIK+ChT+RT (51)	ChT+RT (51)	PFS, ORR
Yuan et al[78]	P	Yes	42	45–78	73.8	–	IV	DC-CIK+ChT (21)	ChT (21)	OS
Yue[79]	P	Yes	110	–	47.3	53.6	III-IV	DC-CIK (55)	BSC (55)	OS, PFS, ORR
Zang et al[80]	P	Yes	90	–	66.7	–	III-IV	DC-CIK+ChT (45)	ChT (45)	OS
Zhang et al[81]	P	Yes	63	24–82	61.9	–	III-IV	DC-CIK+ChT (32)	ChT (31)	OS
Zhang et al[34]	P	Yes	60	–	63.3	56.7	I-IV	CIK+ChT (30)	ChT (30)	OS, SE

Table 1 Continued

Study ID	Study type	RCT	Patient (n)	Age, years (range)	Male (%)	Colon primary (%)	Stage	Intervention arm(s) (n)	Control arm (n)	Outcomes
Zhang et al[82]	R	–	84	–	54.8	–	IV	DC-CIK+ChT (42)	ChT (42)	OS, PFS, ORR, SE
Zhang et al[25]	P	No	112	–	52.2	52.0	III-IV	DC-CIK+ChT (65)	ChT (47)	ORR
Zhang[83]	P	Yes	118	46–78	49.2	–	IV	DC-CIK+ChT (59)	ChT (59)	OS, PFS
Zhang[84]	P	No	90	43–73	67.8	51.1	III-IV	DC-CIK+ChT (45)	ChT (45)	SE
Zhao[87]	P	Yes	30	32–67	70.0	–	IV	DC-CIK+ChT (15)	ChT (15)	ORR
Zhao[35]	P	Yes	122	–	67.2	58.7	IV	CIK+ChT (61)	ChT (61)	ORR, SE
Zhao[85]	P	Yes	90	40–59	63.3	–	IV	CIK+ChT (45)	ChT (45)	ORR, SE
Zhao et al[86]	P	No	148	–	62.8	–	I-III	DC-CIK+ChT+RFA (73)	ChT+RFA (75)	OS
Zhou[89]	P	Yes	60	45–80	68.3	78.3	IV	DC-CIK+ChT (30)	ChT (30)	OS, ORR
Zhou et al[88]	P	No	90	–		–	IV	DC-CIK+TACE (45)	TACE (45)	ORR, SE
Zhu et al[36]	R	–	96	–	57.3	62.1	I-IV	CIK+ChT (21)	ChT (75)	OS, PFS, ORR, SE
Zhu et al[37]	R	–	351	19–92	65.2	30.8	IV	DC-CIK+standard care (100)	Standard care (251)	ORR, SE

*Sixteen and 18 patients in intervention arm and 47 and 35 patients in control arm were treated in adjuvant and palliative setting, respectively.
BSC, best supportive care; ChRT, concurrent chemoradiotherapy; ChT, chemotherapy; CIK, cytokine-induced killer cell; DC-CIK, CIK therapy with autologous dendritic cell therapy; IMRT, intensity-modified radiotherapy; n, number; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; P, prospective; R, retrospective; RCT, randomized controlled trial; RFA, radiofrequency ablation; RT, radiotherapy; TACE, transarterial chemoembolization; U, unknown.

A

B

Figure 2 Comparison of CIK/DC-CIK therapy versus non-CIK/DC-CIK therapy for (A) overall survival (OS) and (B) progression-free survival (PFS). Twenty-six studies involving 3,303 patients and twenty studies involving 2,593 patients contributed data to OS and PFS analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.

Overall survival and progression-free survival

There were 26 studies[17 19 20 27 29 32 33 36 38 39 41 43 47 48 53 55–57 60 63 67 75 77 79 81 86] involving 3303 patients which contributed data to the meta-analysis on OS (figure 2A). The pooled HR was 0.59 (95% CI: 0.53 to 0.65) indicating the OS benefit of CIK/DC-CIK therapy over the control arm. Heterogeneity among the studies was low (I^2=11%, p=0.30). For PFS, 20 studies[18–20 26–30 33–36 56 62 72 74 76 77 82 84] involving 2593 patients contributed the data to the meta-analysis (figure 2B). The pooled HR was 0.55 (95% CI: 0.47 to 0.63), again favoring CIK/DC-CIK therapy. Heterogeneity among the studies was moderate (I^2=54%, p=0.002).

Overall survival rates

In total, 27 (2459 patients),[17 19 20 27 29 32 33 36 38 39 41 43 47–49 53 55–57 60 63 67 75 77 79 81 86] 19 (2167 patients),[17–20 27–29 33 35 36 38 39 41 48 49 56 67 77 86] and 10 (1401 patients)[17–20 27 29 33 36 41 56] studies contributed data for 1-year, 3-year, and 5-year OS rate meta-analyses, respectively (online supplemental figure 2). The pooled RR for all the analyses favored CIK/DC-CIK therapy. The 1-year OS rate was 91.7% in the intervention arm and 79.4% in

the control arm with a pooled RR of 0.47 (95% CI: 0.32 to 0.67). Heterogeneity among the studies was moderate (I^2=51%, p=0.002). The 3-year OS rate was 67.7% in the intervention arm and 51.8% in the control arm with a pooled RR of 0.67 (95% CI: 0.59 to 0.77). There was a moderate level of heterogeneity among the studies (I^2=32%, p=0.09). The 5-year OS rate was 61.2% in the intervention arm and 45.5% in the control arm with an RR of 0.69 (95% CI: 0.54 to 0.88). Heterogeneity among the studies was high (I^2=73%, p=0.0001).

Progression-free survival rates

We identified 10 (1166 patients),[17 19 20 27 29 33 36 37 56 77] 10 (1156 patients),[17 19 20 27–29 33 35 56 77] and 7 (872 patients) studies[17 19 20 27 29 33 56] that contributed data for meta-analysis on 1-year, 3-year, and 5-year PFS rates, respectively (online supplemental figure 3). All the analyses indicated the superiority of CIK/DC-CIK therapy over non-CIK/DC-CIK therapy. The observed 1-year PFS rate was 86.5% in the intervention arm and 68.1% in the control with the pooled RR of 0.43 (95% CI: 0.33 to 0.55). Heterogeneity among the studies was low (I^2=0%, p=0.48). The 3-year PFS rate was 47.8% in the

Study or Subgroup	CIK +/- DC Events	Total	Control Events	Total	Weight	Risk Ratio (Non-event) M-H, Random, 95% CI
Bian 2013	29	42	21	42	2.2%	0.62 [0.36, 1.07]
Cai 2017	28	45	15	45	2.6%	0.57 [0.37, 0.87]
Chen 2014a	16	30	13	30	2.4%	0.82 [0.50, 1.35]
Chen 2014b	35	50	21	50	2.4%	0.52 [0.32, 0.84]
Chu 2016 (1)	25	29	8	15	1.1%	0.30 [0.10, 0.85]
Chu 2016 (2)	16	30	7	15	2.0%	0.88 [0.48, 1.61]
Deng 2018	27	30	18	30	1.0%	0.25 [0.08, 0.80]
Dong 2018	6	20	5	20	2.7%	0.93 [0.64, 1.37]
Du 2013	12	30	11	30	2.7%	0.95 [0.64, 1.41]
Fan 2013	38	41	30	40	0.9%	0.29 [0.09, 0.99]
Feng 2017	22	25	16	25	0.9%	0.33 [0.10, 1.09]
Guo 2019	27	34	20	34	1.6%	0.50 [0.23, 1.08]
He 2018	43	50	31	50	1.6%	0.37 [0.17, 0.80]
Jiang 2016	34	50	19	48	2.5%	0.53 [0.33, 0.84]
Leng 2016	43	45	37	45	0.7%	0.25 [0.06, 1.11]
Liu 2016a	24	29	15	29	1.4%	0.36 [0.15, 0.86]
Liu 2016b	24	40	23	40	2.3%	0.94 [0.56, 1.59]
Liu 2016c	14	45	10	45	3.1%	0.89 [0.69, 1.14]
Liu 2019	21	35	11	35	2.5%	0.58 [0.37, 0.93]
Liu 2020	29	34	20	34	1.4%	0.36 [0.14, 0.88]
Lv 2014	29	43	26	42	2.1%	0.85 [0.48, 1.52]
Ma 2019	21	25	12	25	1.2%	0.31 [0.12, 0.81]
Niu 2016	17	25	9	25	1.9%	0.50 [0.26, 0.95]
Pu 2021	33	49	18	49	2.5%	0.52 [0.33, 0.81]
Sun 2020	26	30	20	30	1.1%	0.40 [0.14, 1.14]
Wang 2014	36	55	28	55	2.5%	0.70 [0.45, 1.11]
Wang 2016	28	52	22	52	2.7%	0.80 [0.55, 1.16]
Wang 2017	20	34	10	34	2.5%	0.58 [0.37, 0.92]
Weng 2013	40	124	25	111	3.3%	0.87 [0.75, 1.02]
Weng 2014	9	48	5	48	3.3%	0.91 [0.77, 1.07]
Wu 2018	38	62	19	70	2.8%	0.53 [0.38, 0.75]
Yan 2014	32	74	10	42	3.1%	0.74 [0.57, 0.97]
Yin 2013	15	40	9	40	3.0%	0.81 [0.60, 1.08]
Yuan 2016	9	20	7	20	2.3%	0.85 [0.51, 1.41]
Yue 2016	1	55	0	55	3.4%	0.98 [0.93, 1.03]
Zang 2019	40	45	31	45	1.3%	0.36 [0.14, 0.91]
Zhang 2011	21	32	13	31	2.2%	0.59 [0.34, 1.04]
Zhang 2015	19	42	12	42	2.8%	0.77 [0.55, 1.07]
Zhang 2016	30	65	21	47	2.8%	0.97 [0.69, 1.37]
Zhang 2017	32	59	20	59	2.9%	0.69 [0.50, 0.97]
Zhao 2015	15	15	15	15		Not estimable
Zhao 2016	10	54	4	51	3.3%	0.88 [0.76, 1.03]
Zhao 2018	43	45	35	45	0.7%	0.20 [0.05, 0.86]
Zhao 2019	47	73	10	75	2.9%	0.41 [0.30, 0.57]
Zhou 2015	14	30	9	30	2.6%	0.76 [0.51, 1.15]
Zhou 2016	21	45	10	45	2.9%	0.69 [0.50, 0.94]
Total (95% CI)		**1975**		**1885**	**100.0%**	**0.65 [0.57, 0.74]**
Total events	1159		751			

Heterogeneity: Tau² = 0.14; Chi² = 299.79, df = 44 (P < 0.00001); I² = 85%
Test for overall effect: Z = 6.28 (P < 0.00001)

Figure 3 CIK/DC-CIK therapy versus non-CIK/DC-CIK therapy for overall response rate (ORR). Forty-five studies involving 3,860 patients contributed data to ORR analysis. *Study Chu 2016 appears twice in the figure as it contained 3 treatment arms and data were entered separately for CIK + chemotherapy versus chemotherapy (Chu 2016 (1)) and CIK versus chemotherapy (Chu 2016 (2)) by splitting the chemotherapy group into 2 subgroups, one for each CIK + chemotherapy and CIK treatment. CIK, cytokine-induced killer cell; DC, dendritic cell.

intervention arm and 30.5% in the control arm. The pooled RR was 0.76 (95% CI: 0.66 to 0.87) and heterogeneity among the studies was moderate (I^2=53%, p=0.02). At 5 years, the PFS rate was 46.0% in the intervention arm and 25.9% in the control arm. The pooled RR was 0.71 (95% CI: 0.59 to 0.87) and heterogeneity among the studies was high (I^2=68%, p=0.005).

Overall response rate

The ORR was 58.7% in the intervention (CIK/DC-CIK) and 39.8% in the control (non-CIK/DC-CIK) arm for 3860 patients from 45 studies[25 26 31 35 40 42–47 50–54 59–66 68–78 85–89 91] (figure 3). The pooled RR was 0.65 (95% CI: 0.57 to 0.74), and heterogeneity among the studies was high (I^2=85%, p<0.00001).

Toxicity

Toxicity during the study intervention was reported by 31 studies with the majority of the data being provided in a descriptive manner. Two studies[18 85] compared the rate of any adverse events between the treatment arms, and 11 studies[30 35 39 40 42 54 59 60 68 70 87 91] reported adverse events of interest for each arm. Many of the described side effects

were thought to be related to chemotherapy administered together with CIK/DC-CIK therapy, including bone marrow suppression, nausea, vomiting, neuropathy, diarrhea, and liver dysfunction. Meta-analysis undertaken indicated equivalent adverse event rate from CIK/DC-CIK and non-CIK/DC-CIK therapy (HR=0.59, 95% CI: 016 to 2.25) with the pooled adverse event rate of 53.5% and 68.3%, respectively (online supplemental figure 4). Heterogeneity was high between the studies (I^2=80%, p=0.02). Fever was the most frequently reported adverse event associated with CIK/DC-CIK infusion, affecting 6.7% to 29.9% of patients receiving CIK/DC-CIK therapy. Fever, in general, spontaneously resolved or only required symptomatic management.

Subgroup analyses

Potential sources of heterogeneity were explored by performing subgroup analysis on OS and PFS by study design (randomized vs non-randomized study design), disease stage (Stage I–III vs Stage IV), CIK therapy type (CIK vs DC-CIK therapy), or timing of CIK/DC-CIK therapy administration (concurrent vs sequential with coadministered anticancer therapy).

9

Randomized studies versus non-randomized studies

Of the 25 studies which provided OS HRs, 8 studies[30 32 34 35 63 66 67 72] involving 991 patients were prospective randomized studies and 17 studies[17–20 27 29 33 37 41 56 58 62 74 76 77 82 84] involving 2252 patients were either prospective non-randomized or retrospective studies. An OS benefit of CIK/DC-CIK therapy was demonstrated for both randomized studies (HR=0.57; 95% CI: 0.50 to 0.66) and non-randomized studies (HR=0.59, 95% CI: 0.51 to 0.67) (figure 4A). A test for

A

Study or Subgroup	log[Hazard Ratio]	SE	CIK +/- DC Total	Control Total	Weight	Hazard Ratio IV, Random, 95% CI
2.2.1 Randomised						
Lin 2016	-0.6162	0.1101	134	121	14.3%	0.54 [0.44, 0.67]
Lv 2014	-0.2107	0.4281	43	42	1.2%	0.81 [0.35, 1.87]
Peng 2017	-1.1087	0.5231	23	23	0.8%	0.33 [0.12, 0.92]
Pu 2021	-0.7765	0.3319	49	49	2.0%	0.46 [0.24, 0.88]
Rui 2012	-0.5798	0.2398	45	45	3.8%	0.56 [0.35, 0.90]
Weng 2013	-0.3711	0.1542	124	111	8.3%	0.69 [0.51, 0.93]
Zhang 2014	-0.9163	0.4074	30	30	1.4%	0.40 [0.18, 0.89]
Zhao 2016	-0.478	0.1987	61	61	5.3%	0.62 [0.42, 0.92]
Subtotal (95% CI)			**509**	**482**	**37.2%**	**0.57 [0.50, 0.66]**
Heterogeneity: Tau² = 0.00; Chi² = 4.89, df = 7 (P = 0.67); I² = 0%						
Test for overall effect: Z = 7.69 (P < 0.00001)						
2.2.2 Non-randomised						
Chao 2016	-0.8675	0.3072	33	33	2.4%	0.42 [0.23, 0.77]
Gao 2014	-1.6607	0.5423	13	13	0.8%	0.19 [0.07, 0.55]
Li 2015	-0.3857	0.1994	65	65	5.3%	0.68 [0.46, 1.01]
Li 2022	-0.5621	0.2345	66	71	3.9%	0.57 [0.36, 0.90]
Liu 2014b	-1.7148	0.6535	9	9	0.5%	0.18 [0.05, 0.65]
Liu 2016c	-0.1165	0.2364	45	45	3.9%	0.89 [0.56, 1.41]
Pan 2020a	-0.7765	0.1685	126	126	7.1%	0.46 [0.33, 0.64]
Pan 2020b	-0.9943	0.3739	60	62	1.6%	0.37 [0.18, 0.77]
Wang 2019	-0.6675	0.2164	97	280	4.6%	0.51 [0.34, 0.78]
Wu 2018	-0.462	0.1949	62	70	5.5%	0.63 [0.43, 0.92]
Xie 2017	-0.478	0.1669	71	71	7.3%	0.62 [0.45, 0.86]
Xu 2021	-0.0202	0.3186	18	35	2.2%	0.98 [0.52, 1.83]
Yin 2013	-0.4005	0.2263	40	40	4.2%	0.67 [0.43, 1.04]
Ying 2010	-0.478	0.2919	51	51	2.6%	0.62 [0.35, 1.10]
Zhang 2015	-0.4943	0.2282	42	42	4.1%	0.61 [0.39, 0.95]
Zhang 2022	-0.3011	0.2209	45	45	4.4%	0.74 [0.48, 1.14]
Zhu 2014	-0.6349	0.3077	100	251	2.4%	0.53 [0.29, 0.97]
Subtotal (95% CI)			**943**	**1309**	**62.8%**	**0.59 [0.51, 0.67]**
Heterogeneity: Tau² = 0.02; Chi² = 20.88, df = 16 (P = 0.18); I² = 23%						
Test for overall effect: Z = 7.73 (P < 0.00001)						
Total (95% CI)			**1452**	**1791**	**100.0%**	**0.58 [0.53, 0.64]**
Heterogeneity: Tau² = 0.00; Chi² = 25.87, df = 24 (P = 0.36); I² = 7%						
Test for overall effect: Z = 11.13 (P < 0.00001)						
Test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.80), I² = 0%						

Favours CIK/DC-CIK   Favours non-CIK/DC-CIK

B

Study or Subgroup	log[Hazard Ratio]	SE	CIK +/- DC Total	Control Total	Weight	Hazard Ratio IV, Random, 95% CI
2.4.1 Randomised						
Du 2013	-0.4308	0.199	30	30	6.0%	0.65 [0.44, 0.96]
Lin 2016	-0.6931	0.1268	134	121	8.0%	0.50 [0.39, 0.64]
Weng 2013	-1.3093	0.1793	124	111	6.5%	0.27 [0.19, 0.38]
Zhang 2014	-1.5606	0.4924	30	30	1.9%	0.21 [0.08, 0.55]
Zhao 2016	-0.1863	0.1829	61	61	6.4%	0.83 [0.58, 1.19]
Subtotal (95% CI)			**379**	**353**	**29.0%**	**0.47 [0.31, 0.72]**
Heterogeneity: Tau² = 0.18; Chi² = 24.32, df = 4 (P < 0.0001); I² = 84%						
Test for overall effect: Z = 3.48 (P = 0.0005)						
2.4.2 Non-randomised						
Gao 2014	-1.6094	0.5161	13	13	1.8%	0.20 [0.07, 0.55]
Li 2015	-0.2485	0.1512	65	65	7.3%	0.78 [0.58, 1.05]
Li 2022	-0.5108	0.233	66	71	5.2%	0.60 [0.38, 0.95]
Liu 2016c	-1.1087	0.3093	45	45	3.8%	0.33 [0.18, 0.61]
Pan 2020a	-0.5798	0.1468	126	126	7.4%	0.56 [0.42, 0.75]
Wang 2019	-0.4813	0.1874	97	280	6.3%	0.62 [0.43, 0.89]
Wu 2018	-0.5621	0.1936	62	70	6.2%	0.57 [0.39, 0.83]
Xie 2017	-0.4943	0.1984	71	71	6.1%	0.61 [0.41, 0.90]
Xu 2021	-0.5798	0.2855	16	47	4.2%	0.56 [0.32, 0.98]
Yin 2013	-0.3857	0.2338	40	40	5.2%	0.68 [0.43, 1.08]
Ying 2010	-0.3711	0.2413	51	51	5.1%	0.69 [0.43, 1.11]
Zhang 2015	-0.6539	0.2477	42	42	4.9%	0.52 [0.32, 0.85]
Zhang 2022	-0.5276	0.1983	45	45	6.1%	0.59 [0.40, 0.87]
Zhu 2013	-1.273	0.6014	21	75	1.4%	0.28 [0.09, 0.91]
Subtotal (95% CI)			**760**	**1041**	**71.0%**	**0.59 [0.52, 0.67]**
Heterogeneity: Tau² = 0.00; Chi² = 14.19, df = 13 (P = 0.36); I² = 8%						
Test for overall effect: Z = 8.55 (P < 0.00001)						
Total (95% CI)			**1139**	**1394**	**100.0%**	**0.54 [0.47, 0.63]**
Heterogeneity: Tau² = 0.06; Chi² = 41.69, df = 18 (P = 0.001); I² = 57%						
Test for overall effect: Z = 7.97 (P < 0.00001)						
Test for subgroup differences: Chi² = 1.05, df = 1 (P = 0.31), I² = 4.5%						

Favours CIK/DC-CIK   Favours non-CIK/DC-CIK

Figure 4 Subgroup analysis by study design for (A) overall survival (OS) and (B) progression-free survival (PFS). Twenty-five studies involving 3,243 patients and nineteen studies involving 2,533 patients contributed data to OS and PFS analysis respectively.

subgroup difference did not reach statistical significance (I^2=0%, p=0.80). For PFS subgroup analysis, 732 patients from five randomized studies[26 30 34 35 72] and 1801 patients from 14 non-randomized studies[18–20 27 29 33 36 56 62 74 76 77 82 84] were analyzed. A benefit from CIK/DC-CIK therapy was again shown for both prospective randomized (HR=0.47, 95% CI: 0.31 to 0.72) and non-randomized studies (HR=0.59, 95% CI: 0.47 to 0.63) (figure 4B). A test for subgroup differences was not statistically significant (I^2=4.5%, p=0.31).

Stage I–III versus Stage IV

Four studies[32 56 63 77] involving 363 patients with Stage I–III CRC and 12 studies[20 28 30 33 35 37 58 66 67 74 76 82] involving 1595 Stage IV patients contributed data to the subgroup analysis on OS by the disease stage. HR for Stage I–III patients was 0.64 (95% CI: 0.48 to 0.85), while that for Stage IV patients was 0.57 (95% CI: 0.50 to 0.65) and the benefit of CIK/DC-CIK therapy was observed across all stages of CRC (online supplemental figure 5A). Test for subgroup differences failed to reach statistical significance (I^2=0%, p=0.48), although the observed 95% CI was much narrower for Stage IV patients. For the subgroup analysis on PFS, four studies[27 33 56 77] involving 321 patients with Stage I–III disease and eight studies[20 26 28 30 35 74 76 82] involving 1045 Stage IV patients were analyzed. A benefit from CIK/DC-CIK therapy was demonstrated for both Stage I–III (HR=0.60, 95% CI: 0.40 to 0.88) and Stage IV disease (HR=0.59, 95% CI: 0.52 to 0.67) (online supplemental figure 5B). A test for subgroup difference was not statistically significant (I^2=0%, p=0.94).

CIK therapy versus DC-CIK therapy

Ten studies[17 18 20 28 29 32 34 35 56 63] (1391 patients) and 16 studies[19 27 30 33 37 41 58 62 66 67 72 74 76 77 82 84] (1912 patients) which evaluated CIK and DC-CIK therapy, respectively, were assessed in the subgroup analysis on OS by the type of CIK therapy. HR for studies examining CIK therapy was 0.57 (95% CI: 0.47 to 0.69), while that for studies examining DC-CIK therapy was 0.61 (95% CI: 0.54 to 0.69) (figure 5A). Both types of CIK therapy were found to benefit OS. A test for subgroup differences did not reach statistical significance (I^2=0%, p=0.58). Subgroup analysis on PFS by CIK therapy type contained nine studies[18 20 26 28 29 34–36 56] involving 1294 patients, where the intervention arm contained CIK therapy, and 11 studies[19 27 30 33 62 72 74 76 77 82 84] involving 1299 patients, where the intervention arm contained DC-CIK therapy. PFS benefit was demonstrated for both CIK-examining (HR=0.63, 95% CI: 0.53 to 0.74) and DC-CIK-examining studies (HR=0.50, 95% CI: 0.41 to 0.61) (figure 5B). A test for subgroup differences met statistical significance (I^2=66.5%, p=0.08) with improved HR seen for DC-CIK, although HRs for the two subgroups overlapped each other, suggesting that the advantage of DC-CIK over CIK therapy alone may not be clinically meaningful.

Concurrent CIK/DC-CIK therapy versus sequential CIK/DC-CIK therapy

Subgroup analysis was performed comparing studies where CIK/DC-CIK therapy was administered either concurrently or sequentially with the non-CIK/DC-CIK therapy. For OS analysis, 16 studies[19 20 28 33 35 37 41 56 58 62 63 67 72 74 82 84] involving 2000 patients with concurrent administration and 8 studies[17 27 29 30 32 34 66 77] involving 846 patients with sequential administration were considered (figure 6A). CIK/DC-CIK therapy administered in either manner improved OS; the HR was 0.63 (95% CI: 0.56 to 071) for concurrent administration and 0.59 (95% CI: 0.53 to 0.65) for sequential administration. A test for subgroup differences reached statistical significance (I^2=76.3%, p=0.04) with lower HR being observed for sequential administration, although 95% CIs of the two subgroups overlapped each other. Subgroup analysis on PFS was similarly in favor of CIK/DC-CIK therapy for both concurrent (HR=0.56, 95% CI: 0.46 to 0.67) and sequential administration (HR=0.54, 95% CI: 0.46 to 0.63) (figure 6B). Twelve studies[19 20 26 28 33 35 56 62 72 74 82 84] involving 1460 patients who had concurrent administration and five studies[27 29 30 34 77] involving 580 patients who had sequential administration were evaluated, and a test for subgroup differences did not meet statistical significance (I^2=0%, p=0.43).

DISCUSSION

Chemotherapy with/without biological therapy remains the standard treatment for patients with CRC with the high-risk resected disease, and the majority of those with advanced disease. This therapeutic approach is associated with limited survival benefit, unlike immunotherapy, which has demonstrated long-term survival outcome in some solid tumors owing to its mechanism of action.[92 93] New therapeutic approaches which involve modulation of the immune system may provide new treatment options for a broader range of patients with CRC and improve their survival outcome. Autologous adoptive immunotherapy such as CIK therapy represents a highly personalized cancer treatment. While it remains a non-standard treatment option for solid cancers, there are a growing number of clinical trials examining such immunotherapy.[94]

Our study demonstrated that providing CIK or DC-CIK therapy to patients with CRC improved OS, PFS, and ORR compared to standard treatment. The upper 95% CI of pooled HRs for 5-year OS rate and 3-year and 5-year PFS rates exceeded 0.85, a commonly applied cut-off to delineate no effect from an important effect, raising the possibility that the observed benefit for these endpoints may not be precise. However, for all the other endpoints, the observed HRs favoring CIK/DC-CIK therapy appeared robust. The OS and PFS benefit of CIK/DC-CIK therapy persisted when prospective randomized studies alone were examined in the subgroup analysis, with no subgroup differences being identified compared with non-randomized studies. While the number of

Figure 5 Subgroup analysis by CIK therapy type (with or without DC therapy) for (A) overall survival (OS) and (B) progression-free survival (PFS). Twenty-six studies involving 3,303 patients and twenty studies involving 2,593 patients contributed data to OS and PFS analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.

randomized studies assessed was small, HRs and associated 95% CIs reported by each study, especially for the OS endpoint, were all comparable, indicating consistency in the results and so strengthening the overall finding.

Subgroup analysis by CRC disease stage indicated a lack of differences for both OS and PFS. However, the observed 95% CIs associated with the pooled HRs were persistently narrower for Stage IV patients compared with Stage I–III patients, with the upper limits of 95% CIs for Stage I–III patients exceeding 0.85 for both endpoints. Together with the uncertainties around the best way to incorporate CIK/DC-CIK therapy into the established 3–6 months of monoadjuvant or doublet-adjuvant chemotherapy,

depending on the disease stage and accompanying other prognostic factors, our study highlights that patients with Stage IV disease may be a more suitable target to evaluate CIK/DC-CIK therapy application, at least initially. The immunosuppressive effect of cancer surgery, including T cell and NK cell dysfunction and expansion of myeloid-derived suppressor cells and regulatory T cells in the postoperative period has been described previously,[95] although how this affects the antitumor activity of CIK/DC-CIK therapy is not known.

Subgroup analysis based on combining DC therapy with CIK therapy revealed statistically significant subgroup differences in favor of DC-CIK over CIK therapy for PFS,

A

B

Figure 6 Subgroup analysis by CIK/DC-CIK therapy administration timing for (A) overall survival (OS) and (B) progression-free survival (PFS). Twenty-four studies involving 2,846 patients and seventeen studies involving 2,040 patients contributed data to OS and PFS analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.

but not for OS. DCs are major antigen-presenting cells and the essential link between the innate and adaptive immune systems.[96] Coculturing of CIK cells with DCs results in increased CIK cytolytic function, including cytotoxic activity against a tumor cell line resistant to CIK cells cultured in the absence of DCs.[14] This review observed more patients who received DC-CIK therapy than CIK therapy; however, the results suggest that the addition of DC therapy to CIK therapy does not have a strong clinical benefit, as only statistical significance was observed for PFS and not for OS. This result points to the need for future clinical trials investigating the benefit of including DC therapy in CIK therapy, and whether other

combinations such as immune checkpoint inhibitors or CAR-T incorporation with CIK therapy may be of better value for patients with CRC.

Subgroup differences were similarly detected for OS for concurrent versus sequential administration of CIK/DC-CIK. Subgroup analyses for both PFS by CIK therapy type and OS by CIK therapy administration timing had similar HRs with highly overlapping 95% CIs, making it unclear whether the differences are clinically meaningful. The timing of CIK/DC-CIK delivery for patients with CRC may not be critical and could be selected based on logistical issues.

There have been two previous publications that systematically reviewed the literature for CIK/DC-CIK therapy in CRC.[16 97] In 2010, Zhang and Schmidt-Wolf, in cooperation with Stanford University, established the International Registry on CIK Cells (IRCC) to evaluate clinical trials of CIK therapy.[97 98] The registry identifies both prospective and retrospective clinical trials involving CIK therapy for cancer treatment from PubMed, Web of Science Core Collection, WHO International Clinical Trials Registry Platform, ClinicalTrials.gov as well as proceedings of the American Society of Clinical Oncology and European Cancer Conference Annual Scientific Meetings. In addition, the IRCC incorporates clinical trials submitted by individual researchers for inclusion.[99] In 2020, the registry recorded 106 clinical trials, of which only 6 examined CIK therapy in patients with CRC.[97] This contrasts with the 29 trials including 2610 patients with CRC reported in the published systematic review and meta-analysis in 2017 by Zhang *et al*, which purely compared the clinical benefit of CIK therapy plus chemotherapy to CIK therapy in patients with CRC with advanced disease.[16] They also used two Chinese databases, CNKI and Wanfang Data, in addition to the English databases Cochrane Library, Embase, and PubMed. The majority of the studies were published in Chinese similar to our findings.

To date, China has taken the lead in research of adoptive immunotherapy including CIK therapy.[15 100] Therefore, the inclusion of articles published in Chinese was necessary to comprehensively review the currently available literature examining the clinical efficacy of CIK therapy in CRC. Additionally, the current work included clinical trials which compared CIK therapy with non-CIK treatment not limited to chemotherapy, to increase the number of trials assessed. Consequently, the review considered 70 studies involving 6743 patients and is the largest systemic review on CIK/DC-CIK therapy in CRC. It meta-analyzed OS and PFS, the two most important clinical endpoints in assessing the efficacy of any cancer therapy. Endpoints covered by Zhang[16] were limited to OS and DFS rates as well as ORR. The CRC population covered by this review is also broader having included patients at all stages.

This study has a number of limitations. The heterogeneity observed in the clinical study design requires caution when interpreting results. There are general guidelines for the production of CIK therapy. The CIK therapy product is generated from PBMCs cultured for 21–28 days in the presence of anti-CD3 stimulation and the cytokines interferon-gamma and interleukin-2. Prior to transfusion, the therapy product is expected to have minimum percentage of NK-like T cells.[101] While having basic production guidelines makes reproducing this therapy achievable, we observed heterogeneity in the culture systems used to generate these cells, including the media, concentration of stimuli and cytokines used, and intervals of cytokine addition in culture. Characterization of the cell therapy product prior to transfusion to meet the guidelines was normally not provided.

Clinical parameters such as anticancer treatment history, demographics, and number of treatment cycles were also observed to be heterogeneous among the studies analyzed. These variables could contribute to the heterogeneity observed in our analysis that was not rectified by our subgroup analyses. As the studies identified were all undertaken in China, clinical trials in non-Chinese ethnicity are needed to confirm its efficacy outside of Chinese patients. Finally, the possibility of publication bias was raised as only a handful of studies reported negative outcomes of CIK/DC-CIK therapy for the efficacy endpoints assessed.

Despite these limitations, our data strongly support that complementing conventional treatment regimens with CIK/DC-CIK therapy in patients with CRC provides clinical benefits. By highlighting the parameters that contribute to the heterogeneity in the study designs, we suggest that standardization of these will lead to greater adoption of CIK therapy worldwide.

CONCLUSION

CIK therapy in combination with standard treatments, in particular chemotherapy, provides clinical benefits for patients with CRC. The benefit existed whether the included studies were prospective and randomized or not, strengthening the finding. CIK therapy was well tolerated, with fever being the most common adverse event. While DC therapy is commonly combined with CIK therapy for patients with CRC, our study suggests that this may not provide extra benefit. The findings support further evaluation of the clinical utility of CIK therapy in CRC.

Competing interests None declared.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

ORCID iDs
Runhao Li http://orcid.org/0000-0001-5577-049X
Kevin Aaron Fenix http://orcid.org/0000-0003-1619-1406

REFERENCES

1 International Agency for Research on Cancer. *The global cancer observatory 2020; colorectal cancer*. 2020.
2 National Cancer Institute. *SEER cancer stat facts: colorectal cancer*. 2022.
3 Sievers CK, Kratz JD, Zurbriggen LD, *et al*. The multidisciplinary management of colorectal cancer: present and future paradigms. *Clin Colon Rectal Surg* 2016;29:232–8.
4 Kruger S, Ilmer M, Kobold S, *et al*. Advances in cancer immunotherapy 2019 - latest trends. *J Exp Clin Cancer Res* 2019;38:268.
5 Chan TA, Yarchoan M, Jaffee E, *et al*. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Ann Oncol* 2019;30:44–56.
6 André T, Shiu K-K, Kim TW, *et al*. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. *N Engl J Med* 2020;383:2207–18.
7 Lenz H-J, Van Cutsem E, Luisa Limon M, *et al*. First-Line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. *JCO* 2022;40:161–70.
8 Fan A, Wang B, Wang X, *et al*. Immunotherapy in colorectal cancer: current achievements and future perspective. *Int J Biol Sci* 2021;17:3837–49.
9 Schmidt-Wolf IG, Negrin RS, Kiem HP, *et al*. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. *J Exp Med* 1991;174:139–49.
10 Gao X, Mi Y, Guo N, *et al*. Cytokine-Induced killer cells as pharmacological tools for cancer immunotherapy. *Front Immunol* 2017;8.
11 Pievani A, Borleri G, Pende D, *et al*. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. *Blood* 2011;118:3301–10.
12 Zhang Q, Wang L, Luo C, *et al*. Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood. *Oncol Rep* 2014;32:2244–52.
13 Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. *Br J Haematol* 2002;116:78–86.
14 Märten A, Ziske C, Schöttker B, *et al*. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. *J Immunother* 2001;24:502–10.
15 Li X-D, Xu B, Wu J, *et al*. Review of chinese clinical trials on CIK cell treatment for malignancies. *Clin Transl Oncol* 2012;14:102–8.
16 Zhang L, Mu Y, Zhang A, *et al*. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in china: a meta-analysis of 29 trials involving 2,610 patients. *Oncotarget* 2017;8:45164–77.
17 Pan Q-Z, Zhao J-J, Yang C-P, *et al*. Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. *Oncoimmunology* 2020;9:1752563.
18 Wang C, Xie L, Wang Y, *et al*. Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer. *Annals of Oncology* 2019;30:ix36.
19 Xie Y, Huang L, Chen L, *et al*. Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. *World J Surg Oncol* 2017;15:209:209.:.
20 Pan Q, Gu J, Zhao J, *et al*. Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer. *Clin Transl Immunol* 2020;9. 10.1002/cti2.1113 Available: https://onlinelibrary.wiley.com/toc/20500068/9/2
21 Page MJ, McKenzie JE, Bossuyt PM, *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
22 Review manager (revman) (v. 5.4.1).
23 Tierney JF, Stewart LA, Ghersi D, *et al*. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;8:16.
24 Altman DG, Bland JM. How to obtain the confidence interval from a p value. *BMJ* 2011;343:d2090.
25 Zhang L, Li X, Huang K, *et al*. Long-term effect of DC-CIK cells immunology therapy in patients with advanced colorectal cancer (Chinese article). *Progress in Modern Biomedicine* 2016;16:4348–51.
26 Du C, Liu Z, Ding Z, *et al*. Autologous cytokine-induced killer cells combined with chemotherapy in the treatment of advanced colorectal cancer: a randomized control study. *Chin -Ger J Clin Oncol* 2013;12:487–91.
27 Gao D, Li C, Xie X, *et al*. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. *PLoS ONE* 2014;9:e93886.
28 Li X, Dai X, Shi L, *et al*. Phase II/III study of radiofrequency ablation combined with cytokine-induced killer cells treating colorectal liver metastases. *Cell Physiol Biochem* 2016;40:137–45.
29 Li X, Zhou H, Huang W, *et al*. Retrospective analysis of the efficacy of adjuvant cytokine-induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery. *Clin & Trans Imm* 2022;11. 10.1002/cti2.1368 Available: https://onlinelibrary.wiley.com/toc/20500068/11/1
30 Lin T, Song C, Chuo DY, *et al*. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. *Tumour Biol* 2016;37:4367–72.
31 Lin T, Song C, Chuo D-Y, *et al*. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. *Tumour Biol* 2016;37:4367–72.
32 Peng H, Yao M, Fan H, *et al*. Effects of autologous cytokine-induced killer cells infusion in colorectal cancer patients: a prospective study. *Cancer Biotherapy and Radiopharmaceuticals* 2017;32:221–6.
33 Xu H, Qin W, Feng H, *et al*. Analysis of the clinical efficacy of dendritic cell –cytokine induced killer cell-based adoptive immunotherapy for colorectal cancer. *Immunological Investigations* 2021;50:622–33.
34 Zhang J, Zhu L, Zhang Q, *et al*. Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study. *Biomedicine & Pharmacotherapy* 2014;68:715–20.
35 Zhao H, Wang Y, Yu J, *et al*. Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial. *Clin Colorectal Cancer* 2016;15:228–35.
36 Zhu Y, Zhang H, Li Y, *et al*. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer. *Cancer Immunol Immunother* 2013;62:1629–35.
37 Zhu H, Yang X, Li J, *et al*. Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. *Biomed Res Int* 2014;2014:603871.
38 Cai X, Xiong W, Li Y, *et al*. Clinical research of the treatment on patients of mid-low locally rectal cancer after operation with cytokine induced killer cells (Chinese article). *The Practical Journal of Cancer* 2010;25:37–9.
39 Cai W, Li W. Clinical study of autologous CIK cells combined with synchronous radiotherapy and chemotherapy in the treatment of elderly rectal cancer patients (Chinese article). *Modern Preventive Medicine* 2013;40:1564–7.
40 Cai P. Clinical observation of DC-CIK combined with chemotherapy on advanced colon cancer (Chinese article). *World Latest Medicine Information* 2017;17:155–6.
41 Chao Y, Yang X, Zhou F, *et al*. The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors (Chinese article). *Journal of Pharmaceutical Practice* 2016;34:366–71.
42 Chen F, Jiang QQ, Jiao L, *et al*. Dendritic cell - cytokine induced killer cells combined with chemotherapy and targeted therapy in treatment of advanced colon cancer patients (Chinese article). *Modern Oncology* 2014;23:1686–90.
43 Chen Y. Clinical study of DC-CIK combined with chemotherapy in the treatment of colon cancer (Chinese article). *Health For Everyone* 2014;14.
44 Chu F, Liang Q, Wang L, *et al*. Effect of mfolfox6 chemotherapy combined with autologous CIK cells on T lymphocyte subsets in patients with advanced colorectal cancer (Chinese article). *World Chinese Digestive Journal* 2016;24:2279–85.
45 Deng Z, Liao Q, Liu J. Evaluation of the efficacy of CIK cell sequential systemic chemotherapy in advanced colorectal cancer (Chinese article). *China Health Nutrition* 2018;28:62.

46 Dong M. Efficacy of DC-CIK adoptive immunotherapy in combination with chemotherapy in the treatment of metastatic colorectal cancer (Chinese article). *Dietary Health Care* 2018;5:49.

47 Fan M, Ye W, Yao J, *et al*. Clinical analysis of cytokine induced killer cells combined with concurrent chemoradiotherapy in the treatment of local recurrance of rectal neoplasms (Chinese article). *Chin J Postgrad Med* 2013;36:21–5.

48 Fang L. Observation of the efficacy of CIK cell immunotherapy on postoperative rectal cancer (Chinese article). *The World Clinical Medicine* 2016;10:41.

49 Feng Y, Zhu Z, Sun B, *et al*. Efficacy evaluation of CIK cell immunotherapy for postoperative rectal cancer (Chinese article). *Clin Res* 2014:366–7.

50 Feng F, Wang W. Clinical observation of chemotherapy combined with DC-CIK cell immunotherapy for stage III colorectal cancer (Chinese article). *Modern Diagnosis and Treatment* 2017;28:3832–3.

51 Guo J, Ma L. Efficacy of dendritic cell-cytokine-induced killer cell biology combined with portal vein embolization on liver metastasis of colorectal cancer (Chinese article). *Sanxi Med J* 2019;48:936–8.

52 He J, Zhang C. Analysis of the effect of postoperative chemotherapy combined with DC-CIK cell therapy for colorectal cancer (Chinese article). *J Med Theor & Prac* 2018;31:2545–6.

53 Jiang Y. Efficacy of DC-CIK cells in the treatment of advanced colorectal cancer (Chinese article). *Front Med* 2016;6:230–1.

54 Leng N, Nie W, Zhao Y, *et al*. The effect of mcik combined with IMRT and microwave hyperthemia in the treatment of locally advanced rectal cancer (Chinese article). *Oncology Progress* 2016;14:861–3.

55 Li S, Li Y, Liang J, *et al*. The study of clinical application of DC-CIK combined with chemotherapy on colon cancer (Chinese article). *Chinese Journal of Immunology* 2012;28:835–9.

56 Li Y, Jin A, Chen S, *et al*. Efficacy of adjuvant chemotherapy combined with CIK cell immunotherapy in 130 patients with postoperative colorectal cancer (Chinese article). *Journal of Chinese Oncology* 2015;21:843–7.

57 Liu W. Clinical effect of the application of DC-CIK combined with chemotherapy in the treatment of colon cancer (Chinese article). *China Continuing Medical Education* 2014;6:43–4.

58 Liu G, Li Y, Chen Z, *et al*. Clinical efficacy of DC-CIK cells combined with systemic intravenous chemotherapy in the treatment of advanced colorectal cancer with diffuse liver metastasis (Chinese article). *Journal of Chongqing Medical University* 2014;39:368–73.

59 Liu C. Effect of DC-CIK combined with FOLFOX6 chemotherapy regimen in the treatment of elderly colorectal cancer patients (Chinese article). *Medical Journal of Chinese People's Health* 2020;32:55–7.

60 Liu Y, Ge S, Liu Q. Efficacy of transcatheter arterial chemoembolization combined with DC-CIK for colorectal cancer patients with liver metastasis (Chinese article). *The Practical Journal of Cancer* 2016;31:1277–9.

61 Liu R, Shi N. Efficacy of dendritic cells and cytokine induced killer cells combination chemotherapy for colon cancer and influences on immune function changes (Chinese article). *Chin J Clin Oncol Rehali* 2016;23:401–4.

62 Liu D, Sun Z, Li Y, *et al*. Clinical efficacy of postoperative chemotherapy in combination with CIK immunotherapy in rectal cancer patients (Chinese article). *Chinese Journal of General Surgery* 2016;25:1186–92.

63 Lv Y, Shi Y, Wang Z, *et al*. A randomised study of cytokine-induced killer cells combined with chemotherapy for advanced colorectal cancer. *Oncology Progress* 2014:505–10.

64 Ma J. DC-CIK combined with chemotherapy for colonic cancer:an analysis on the efect of 25 cases. *Clin J Coloproctol* 2019;39:8–9.

65 Niu S. DC-CIK combined with chemotherapy plus targeted therapy is used for advanced colon cancer (Chinese article). *Journal of Basic and Clinical Oncology* 2016;29:355–6.

66 Pu L, Jin L, Li T, *et al*. The effect of DC-CIK combined with chemotherapy on patients with liver metastases after radical resection of colorectal cancer and its influence on the expression of TRF1 and TRF2 (Chinese article). *Chin J Diffc and Compl Cas* 2021;20:446–9.

67 Rui T, Wu GQ, Xu J, *et al*. Activated DC combined with CIK immunotherapy for patients with advanced colorectal cancer (Chinese article). *Zhejiang Medicine* 2012;37:1505–9.

68 Sun J. The effect of DC-CIK combined with chemotherapy plus targeted therapy was observed in patients with advanced colon cancer (Chinese article). *Dietary Health Care* 2020;46:36.

69 Wang R, Meng MY, Li P, *et al*. Effects of IL-2- and IL-15-induced CIK cells combined with chemotherapy treatment for colorectal cancer (Chinese article). *Journal of Junming Medical University* 2014;35:97–101.

70 Wang L, Zhao D, Cao Y, *et al*. The application of DC-CIK biological immunotherapy combined with chemotherapy and targeted therapy in advanced colon cancer (Chinese article). *International Herald of Medicine and Health (IMHGN)* 2016;22:42–4.

71 Wang X, Zhang J, Hui L, *et al*. Effect of chemotherapy combined with DC-CIK cell immunotherapy on advanced colorectal cancer and immune function (Chinese article). *Med J NDFNC* 2017;38:351–6.

72 Weng H, Shen D, Mao W, *et al*. Clinical efficacy of DC-CIK immunotherapy combined with chemotherapy in treatment of advanced colorectal cancer (Chinese article). *Zhejiang Medicine* 2013;37:625–9.

73 Weng J, Yu LW, Li YP, *et al*. Clinical observation of co-treatment with CIK cells and dendritic cells for advanced rectal cancer (Chinese article). *Chin J Clin Oncol Rehali* 2014;21:1040–3.

74 Wu Y. Influence of DC-CIK on circulating tumour cells in patients with liver metastasis after radical resection of colorectal cancer and its therapeutic efficacy (Chinese article). *Chin J Cancer Biother* 2018;25:89–93.

75 Yan H, Wu J, Sun W, *et al*. Clinical observation of elderly patients with advanced colorectal cancer treated with CIK cells combined with chemotherapy (Chinese article). *Journal of Basic and Clinical Oncology* 2014;27:286–8.

76 Yin L. Efficacy of dendritic cells/cytokine induced killer cells adoptive immunotherapy combined with chemotherapy in treatment of metastatic colorectal cancer (Chinese article). *Clin J Cancer Biother* 2013;20:217–24.

77 Ying M, Wei Z, Yang J, *et al*. Retrospective analysis of pos-operative chemo-radiotherapy combined with DC-CIK in the treatment of patients with colorectal cancer (Chinese article). *The Practical Journal of Cancer* 2010;25:274–6.

78 Yuan J, Peng D, Li J, *et al*. Clinical research of dendritic cells combined with cytokine induced killer cells therapy for advanced colorectal cancer (Chinese article). *Chinese General Practice* 2016;14:4139–41.

79 Yue L*et al*. Clinical research of adoptive immunotherapy with killer cells induced by autologous dendritic cells vaccine in palliative care of elder patients with colorectal carcinoma (chinese article). *Sichuan Medical Journal* 2016;37:1228–32.

80 Zang Y, Ding L, Jiang Z. Clinical efficacy of DC - CIK combined with FOLFOX6 chemotherapy in treatment of elderly patients with colorectal cancer and its effect on serum hcap18 and APE1 autoantibodies (Chinese article). *Journal of Practical Oncology* 2019;34:449–53.

81 Zhang J, Geng J, Han Z, *et al*. Observation of clinical efficacy of chemotherapy combined with CIK/DC cell therapy for advanced colon cancer (Chinese article). *ACTA Academia Medicine XUZHOU* 2011;31:457–9.

82 Zhang J, Ye Z, Huang L, *et al*. Clinical discussion of DC-CIK cell combination chemotherapy in the treatment of advanced colorectal cancer (Chinese article). *Zhejiang Clinical Medicine* 2015;17:2105–6.

83 Zhang W. Clinical observation of DC-CIK adoptive immunotherapy combined with chemotherapy in the treatment of advanced colorectal cancer (chinese article). *Practical Integrative Medicine Clinical* 2017;17:47–8.

84 Zhang Z. Clinical efficacy of dendritic cells/cytokine induced killer cells immunotherapy combined with chemotherapy for advanced colorectal cancer (Chinese article). *Med J West China* 2022;34:415–9.

85 Zhao B. Clinical efficacy of DC-CIK combined with chemotherapy and targeted therapy for advanced colon cancer (Chinese article). *Heilongjiang Medicine and Pharmacy* 2018;41:5–6.

86 Zhao H, Yun S, Li C, *et al*. Efficacy of DC-CIK combined with chemotherapy and radiofrequency ablation in the treatment of postoperative liver metastasis of colorectal cancer (Chinese article). *Modern Instruments and Medical* 2019;25:57–61.

87 Zhao W. To explore the effect of DC-CIK combine with chemotherapy plus targeted therapy for advanced colorectal cancer (Chinese article). *China Continuing Medical Education* 2015;7:93–5.

88 Zhou D, Cao S, Li Q, *et al*. Clinical study of TACE combined with DC-CIK biotherapy on the treatment of patients with clorectal liver metastases. *Journal of Clinical Radiology* 2016;35:771–4.

89 Zhou Q. Observation effect of biological immune method in the treatment of patients with advanced colorectal cancer (Chinese article). *Contemporary Chinese Medicine* 2015;22:37–9.

90 Guo R, Piao H, Shi G, *et al*. Analysis of the efficacy of CIK therapy in adjuvant treatment of colorectal cancer. *JCO* 2020;38:e15022.

91 Bian J. Study on chemotherapy combined with DC-CIK on colorectal cancer (Chinese article). *Chin J Surg Onco* 2013;5:306–9.

92 Larkin J, Chiarion-Sileni V, Gonzalez R, *et al*. Five-Year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med* 2019;381:1535–46.

93 Reck M, Rodríguez-Abreu D, Robinson AG, *et al*. Five-Year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50 %. *JCO* 2021;39:2339–49.

94 Xin Yu J, Hubbard-Lucey VM, Tang J. The global pipeline of cell therapies for cancer. *Nat Rev Drug Discov* 2019;18:821–2.

95 Bakos O, Lawson C, Rouleau S, *et al*. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. *J Immunother Cancer* 2018;6:86.

96 Patente TA, Pinho MP, Oliveira AA, *et al*. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. *Front Immunol* 2018;9:3176.

97 Zhang Y, Schmidt-Wolf IGH. Ten-Year update of the International registry on cytokine-induced killer cells in cancer immunotherapy. *J Cell Physiol* 2020;235:9291–303.

98 Wolf B, Zimmermann S, Arber C, *et al*. Safety and tolerability of adoptive cell therapy in cancer. *Drug Saf* 2019;42:315–34.

99 Oncology, C. B. C. f. I. IRCC – international registry on CIK cells. 2009. Available: https://cik-info.org/en/ircc international-registry-on-cik-cells/

100 Wei J, Guo Y, Wang Y, *et al*. Clinical development of CAR T cell therapy in China: 2020 update. *Cell Mol Immunol* 2021;18:792–804.

101 Mareschi K, Adamini A, Castiglia S, *et al*. Cytokine-Induced killer (CIK) cells, in vitro expanded under good manufacturing process (GMP) conditions, remain stable over time after cryopreservation. *Pharmaceuticals (Basel)* 2020;13:93.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplementary Data

Supplementary Tables

Supplementary Table 1. Search strategy for Embase

#1	Cytokine-Induced Killer Cells/
#2	cytokine induced killer cell*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
#3	(cytokine induced adj6 killer cell*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]
#4	2 or 3
#5	1 or 4
#6	*colorectal cancer*/ or colorectal neoplasm*.mp. or colon cancer*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]
#7	exp colon tumor/
#8	exp rectum tumor/
#9	6 or 7 or 8
#10	5 or 9

Supplementary Table 2. Search strategy for MEDLINE

#1	Cytokine-Induced Killer Cells/
#2	cytokine induced killer cell*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol
#3	(cytokine induced adj6 killer cell*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
#4	2 or 3
#5	1 or 4
#6	exp Colorectal Neoplasms/
#7	*colorectal cancer*/ or colorectal neoplasm*.mp. or colon cancer*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
#8	6 or 7
#9	5 and 8

Supplementary Figures

Supplementary Figure 1. Risk of bias assessment summary

A

Study or Subgroup	CIK +/- DC Events	Total	Control Events	Total	Weight	Risk Ratio (Non-event) M-H, Random, 95% CI
Cai 2010	37	40	35	40	4.4%	0.60 [0.15, 2.34]
Cai 2013	40	40	31	32	1.2%	0.27 [0.01, 6.37]
Chao 2016	33	33	11	33	1.5%	0.02 [0.00, 0.35]
Chen 2014b	50	50	15	50	1.5%	0.01 [0.00, 0.22]
Fan 2013	37	41	34	40	5.1%	0.65 [0.20, 2.13]
Fang 2016	25	26	23	26	2.2%	0.33 [0.04, 3.00]
Feng 2014	20	20	20	20		Not estimable
Gao 2014	13	13	11	13	1.3%	0.20 [0.01, 3.80]
Jiang 2016	44	50	32	48	7.0%	0.36 [0.15, 0.84]
Li 2012	20	20	19	20	1.2%	0.33 [0.01, 7.72]
Li 2015	64	65	62	65	2.1%	0.33 [0.04, 3.12]
Li 2022	62	66	69	71	3.4%	2.15 [0.41, 11.36]
Liu 2014a	28	28	27	28	1.2%	0.33 [0.01, 7.85]
Liu 2016a	21	29	14	29	8.1%	0.53 [0.27, 1.06]
Lv 2014	40	43	35	42	4.7%	0.42 [0.12, 1.51]
Pan 2020a	123	126	97	126	5.3%	0.10 [0.03, 0.33]
Pan 2020b	59	60	61	62	1.5%	1.03 [0.07, 16.15]
Peng 2017	23	23	23	23		Not estimable
Rui 2012	40	45	37	45	5.9%	0.63 [0.22, 1.76]
Xie 2017	60	71	46	71	8.5%	0.44 [0.23, 0.82]
Xu 2021	11	18	31	35	5.6%	3.40 [1.15, 10.11]
Yan 2014	56	72	23	42	9.0%	0.49 [0.28, 0.85]
Ying 2010	51	51	51	51		Not estimable
Yue 2016	32	55	21	55	10.1%	0.68 [0.47, 0.98]
Zhang 2011	31	32	28	31	2.2%	0.32 [0.04, 2.94]
Zhao 2019	69	73	62	75	5.7%	0.32 [0.11, 0.92]
Zhu 2013	21	21	73	75	1.3%	0.69 [0.03, 13.86]
Total (95% CI)		1211		1248	100.0%	0.47 [0.32, 0.67]
Total events	1110		991			

Heterogeneity: Tau² = 0.31; Chi² = 46.86, df = 23 (P = 0.002); I² = 51%
Test for overall effect: Z = 4.09 (P < 0.0001)

Favours CIK/DC-CIK   Favours non-CIK/DC-CIK

B

Study or Subgroup	CIK +/- DC Events	Total	Control Events	Total	Weight	Risk Ratio (Non-event) M-H, Random, 95% CI
Zhu 2013	21	21	64	75	0.2%	0.15 [0.01, 2.45]
Pan 2020b	58	60	52	62	0.8%	0.21 [0.05, 0.90]
Fang 2016	23	26	17	26	1.2%	0.33 [0.10, 1.09]
Feng 2014	16	20	14	20	1.3%	0.67 [0.22, 2.01]
Gao 2014	10	13	3	13	1.5%	0.30 [0.11, 0.85]
Li 2016	24	30	20	30	2.0%	0.60 [0.25, 1.44]
Ying 2010	45	51	35	51	2.1%	0.38 [0.16, 0.88]
Cai 2010	30	40	25	40	3.2%	0.67 [0.34, 1.30]
Cai 2013	30	40	18	32	3.3%	0.57 [0.29, 1.11]
Li 2015	52	65	41	65	4.1%	0.54 [0.30, 0.97]
Li 2022	48	66	47	71	5.0%	0.81 [0.48, 1.34]
Xu 2021	6	18	16	35	6.0%	1.23 [0.79, 1.92]
Zhao 2019	48	73	37	75	7.2%	0.68 [0.46, 1.00]
Chao 2016	16	33	5	33	7.9%	0.61 [0.42, 0.87]
Wang 2019	65	97	151	280	9.4%	0.72 [0.52, 0.98]
Zhao 2016	30	61	14	61	10.3%	0.66 [0.50, 0.87]
Pan 2020a	79	126	42	126	11.2%	0.56 [0.43, 0.72]
Xie 2017	33	71	17	71	11.3%	0.70 [0.55, 0.91]
Rui 2012	13	45	9	45	12.0%	0.89 [0.70, 1.13]
Total (95% CI)		956		1211	100.0%	0.67 [0.59, 0.77]
Total events	647		627			

Heterogeneity: Tau² = 0.02; Chi² = 26.63, df = 18 (P = 0.09); I² = 32%
Test for overall effect: Z = 5.93 (P < 0.00001)

Favours CIK/DC-CIK   Favours non-CIK/DC-CIK

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

C

Study or Subgroup	CIK +/- DC Events	Total	Control Events	Total	Weight	Risk Ratio (Non-event) M-H, Random, 95% CI
Chao 2016	10	33	20	33	10.1%	1.77 [1.10, 2.86]
Gao 2014	10	13	2	13	4.2%	0.27 [0.10, 0.76]
Li 2015	43	65	29	65	11.4%	0.61 [0.41, 0.92]
Li 2022	44	66	32	71	11.5%	0.61 [0.41, 0.91]
Pan 2020a	63	126	33	126	15.0%	0.68 [0.55, 0.83]
Pan 2020b	53	60	45	62	5.8%	0.43 [0.19, 0.95]
Wang 2019	72	97	142	280	12.3%	0.52 [0.37, 0.75]
Xie 2017	30	71	14	71	14.6%	0.72 [0.57, 0.91]
Xu 2021	3	18	4	35	14.5%	0.94 [0.74, 1.19]
Zhu 2013	21	21	57	75	0.7%	0.09 [0.01, 1.49]
Total (95% CI)		570		831	100.0%	0.69 [0.54, 0.88]
Total events	349		378			

Heterogeneity: Tau² = 0.09; Chi² = 33.52, df = 9 (P = 0.0001); I² = 73%
Test for overall effect: Z = 3.04 (P = 0.002)

**Supplementary Figure 2.** CIK/DC-CIK therapy versus non-CIK/DC-CIK therapy for (A) 1-year, (B) 3-year and (C) 5-year overall survival (OS) rates. Twenty-seven studies involving 2,459 patients, nineteen studies involving 2,167 patients and ten studies involving 1,401 patients contributed data to 1-, 3- and 5-year OS rate analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.

A

Study or Subgroup	CIK +/- DC Events	Total	Control Events	Total	Weight	Risk Ratio (Non-event) M-H, Random, 95% CI
Gao 2014	13	13	11	13	0.7%	0.20 [0.01, 3.80]
Li 2015	53	65	41	65	17.2%	0.50 [0.27, 0.91]
Li 2022	55	66	59	71	11.1%	0.99 [0.47, 2.08]
Pan 2020a	107	126	70	126	29.6%	0.34 [0.21, 0.54]
Pan 2020b	59	60	53	62	1.5%	0.11 [0.02, 0.88]
Xie 2017	61	71	46	71	14.5%	0.40 [0.21, 0.77]
Xu 2021	14	16	35	47	3.2%	0.49 [0.12, 1.96]
Ying 2010	41	51	28	51	15.5%	0.43 [0.23, 0.82]
Zhu 2013	19	21	52	75	3.3%	0.31 [0.08, 1.21]
Zhu 2014	19	21	52	75	3.3%	0.31 [0.08, 1.21]
Total (95% CI)		**510**		**656**	**100.0%**	**0.43 [0.33, 0.55]**
Total events	441		447			

Heterogeneity: Tau² = 0.00; Chi² = 8.50, df = 9 (P = 0.48); I² = 0%
Test for overall effect: Z = 6.66 (P < 0.00001)

Favours CIK/DC-CIK — Favours non-CIK/DC-CIK (0.001, 0.1, 1, 10, 1000)

B

Study or Subgroup	CIK +/- DC Events	Total	Control Events	Total	Weight	Risk Ratio (Non-event) M-H, Random, 95% CI
Gao 2014	9	13	2	13	2.3%	0.36 [0.16, 0.85]
Li 2015	28	65	18	65	12.4%	0.79 [0.61, 1.02]
Li 2016	6	30	4	30	13.8%	0.92 [0.74, 1.16]
Li 2022	43	66	35	71	7.7%	0.69 [0.46, 1.03]
Pan 2020a	45	126	25	126	17.3%	0.80 [0.69, 0.94]
Pan 2020b	48	60	32	62	4.6%	0.41 [0.23, 0.73]
Xie 2017	46	71	31	71	8.3%	0.63 [0.43, 0.91]
Xu 2021	8	16	13	47	5.3%	0.69 [0.41, 1.16]
Ying 2010	22	51	14	51	11.1%	0.78 [0.58, 1.05]
Zhao 2016	12	61	8	61	17.2%	0.92 [0.79, 1.08]
Total (95% CI)		**559**		**597**	**100.0%**	**0.76 [0.66, 0.87]**
Total events	267		182			

Heterogeneity: Tau² = 0.02; Chi² = 19.20, df = 9 (P = 0.02); I² = 53%
Test for overall effect: Z = 3.87 (P = 0.0001)

Favours CIK/DC-CIK — Favours non-CIK/DC-CIK (0.05, 0.2, 1, 5, 20)

C

Study or Subgroup	CIK +/- DC Events	Total	Control Events	Total	Weight	Risk Ratio (Non-event) M-H, Random, 95% CI
Gao 2014	9	13	1	13	4.5%	0.33 [0.15, 0.76]
Li 2015	20	65	12	65	19.7%	0.85 [0.70, 1.04]
Li 2022	37	66	28	71	14.4%	0.73 [0.52, 1.01]
Pan 2020a	33	126	21	126	22.3%	0.89 [0.78, 1.01]
Pan 2020b	48	60	30	62	8.1%	0.39 [0.22, 0.68]
Xie 2017	41	71	24	71	14.9%	0.64 [0.46, 0.88]
Xu 2021	4	16	2	47	16.0%	0.78 [0.59, 1.05]
Total (95% CI)		**417**		**455**	**100.0%**	**0.71 [0.59, 0.87]**
Total events	192		118			

Heterogeneity: Tau² = 0.04; Chi² = 18.59, df = 6 (P = 0.005); I² = 68%
Test for overall effect: Z = 3.41 (P = 0.0007)

Favours CIK/DC-CIK — Favours non-CIK/DC-CIK (0.05, 0.2, 1, 5, 20)

Supplementary Figure 3. CIK/DC-CIK therapy versus non-CIK/DC-CIK therapy for (A) 1-year, (B) 3-year and (C) 5-year progression-free survival (PFS) rates. Ten studies involving 1,166 patients, ten studies involving 1,156 patients and seven studies involving 872 patients contributed data to 1-, 3- and 5-year PFS rate analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplementary Figure 4. CIK/DC-CIK therapy versus non-CIK/DC-CIK therapy on any adverse events. Two studies involving 467 patients contributed data to any adverse events analysis. CIK, cytokine-induced killer cell; DC, dendritic cell.

A

B

Supplementary Figure 5. Subgroup analysis by disease stage for (A) overall survival (OS) and (B) progression-free survival (PFS) between CIK/DC-CIK therapy versus non-CIK/DC-CIK therapy. Sixteen studies involving 1,958 patients and twelve studies involving 1,366 patients contributed data to OS and PFS analysis respectively. CIK, cytokine-induced killer cell; DC, dendritic cell.